Clin2
NCT05855330Possibly a fitRecruiting

Arginine treatment for kids hospitalized with COVID-19

COVID-19

Part of Infections, Lungs & breathing clinical trials.

This Phase 2 trial tests whether replacing the body’s arginine (an amino acid) can improve outcomes for children and young adults hospitalized with COVID-19. It may help the immune response, but you must meet several safety criteria to join.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
21 people
Ages
3 years to 21 years
Study type
Interventional

Who can take part

  • You must be age 3 to 21 and have an established COVID-19 diagnosis
  • You must be going to the hospital specifically for COVID-19 treatment
  • You cannot have severe liver problems (ALT more than 6 times normal)
  • You cannot have significant kidney problems (creatinine more than 1.5 times normal) or be on dialysis
  • You cannot be pregnant
  • You cannot have certain major medical histories (for example severe allergic reaction to arginine, recent stroke, major heart disease, major lung disease like cystic fibrosis or sickle cell lung issues, or an organ transplant)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05261139Recruiting· Phase 3
Trial for PF-07321332 for children at risk from COVID-19

This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.

Phoenix, Arizona
NCT02447874Recruiting· Phase 1/Phase 2
Arginine treatment for children’s sickle cell pain

This early-phase study tests whether arginine can help control pain in children with sickle cell disease. You may be considered if your child is having a sickle cell pain episode that needs stronger pain medicine given through an IV.

Atlanta, Georgia
NCT07573059Recruiting
Safety study of a test system for Loargys-treated patients

This study evaluates whether a new test system is safe to use in patients who are already taking Loargys (a medicine for a rare condition called ARG1-D, which affects how the body processes a protein building block called arginine). The study simply observes how the test system works in people already on this treatment.

Atlanta, Georgia
NCT06426147Recruiting
Citrulline for hospitalized children with fever

This trial tests if L-citrulline, a natural substance, can help young children (1 month to 5 years) who are hospitalized with fever and are at moderate to high risk for severe illness. It aims to improve their recovery and reduce complications.

Harar
NCT05306925Recruiting
Arginine supplement study for newborns after major gut surgery

This study looks at whether giving an amino-acid supplement called arginine to newborns after major bowel surgery can improve the baby’s immune response. It may help doctors understand how to support recovery after conditions like necrotizing enterocolitis or certain birth defects.

Liverpool, Merseyside
NCT07394270Not yet recruiting· Phase 2
L-Arginine for heart failure patients with low pump function

This trial tests whether adding L-arginine, a natural amino acid, to your usual heart failure treatment can help your heart pump better. It is for people with moderate to severe heart failure and stable kidney function.

Cairo

Hear when a new COVID-19 trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.